Military Nutrition Division, US Army Research Institute of Environmental Medicine, Kansas St., Natick, MA 01760, USA.
J Acad Nutr Diet. 2012 Apr;112(4):533-40. doi: 10.1016/j.jada.2011.10.006. Epub 2012 Feb 2.
A higher body mass index is associated with exercise-related injuries and increased risk for musculoskeletal and connective tissue disorders, which are relevant to military personnel. Studies show the efficacy of orlistat 60 mg for promoting weight and body fat loss in civilians; however, its efficacy among predominantly young, male soldiers is unknown. This study's objective was to examine the effect of a 6-month, standard education-based weight-management program with and without orlistat 60 mg on changes in weight and body fat in overweight soldiers. Data were collected for this randomized, controlled trial from March 2008 to November 2010 at Fort Bragg, NC. Participants were enrolled in an education-based weight management program (n=435; 75% men) and were randomized to placebo or orlistat 60 mg, three capsules daily with meals. All participants were recommended to maintain a reduced-energy, low-fat diet. Among study completers (14% retention rate; placebo n=22, orlistat n=35) members of both groups lost significant weight from baseline (placebo -3.0±5.2 kg; orlistat -3.2±4.7 kg; P<0.01), but only the orlistat group lost fat mass (-2.5±3.9 kg; P<0.001), whereas the placebo group lost lean mass (-1.4±2.7 kg; P <0.01). An intent-to-treat analysis (?1 follow-up body weight measure) demonstrated that the orlistat group lost more fat mass vs the placebo group (-1.3±2.9 kg vs ?0.6±1.8 kg, respectively; P<0.05), but less lean mass (-0.2±2.0 kg vs -0.8±1.8 kg, respectively; P<0.01). Orlistat 60 mg may be an effective adjunct to an education-based weight management program in a mostly young, male soldier population.
更高的体重指数与运动相关的损伤和肌肉骨骼及结缔组织疾病的风险增加有关，这与军人有关。研究表明，奥利司他 60 毫克对促进平民的体重和体脂减少是有效的；然而，其在主要为年轻男性士兵中的疗效尚不清楚。本研究的目的是检查为期 6 个月的标准教育为基础的体重管理计划，以及是否添加奥利司他 60 毫克，对超重士兵体重和体脂的变化的影响。这项随机对照试验的数据是 2008 年 3 月至 2010 年 11 月在北卡罗来纳州布拉格堡收集的。参与者参加了一个基于教育的体重管理计划（n=435；75%为男性），并随机分为安慰剂或奥利司他 60 毫克组，每天三餐时服用三粒胶囊。所有参与者都被建议保持低能量、低脂肪饮食。在研究完成者（保留率 14%；安慰剂组 n=22，奥利司他组 n=35）中，两组从基线开始体重均显著下降（安慰剂组-3.0±5.2 千克；奥利司他组-3.2±4.7 千克；P<0.01），但只有奥利司他组减少了脂肪量（-2.5±3.9 千克；P<0.001），而安慰剂组减少了瘦体重（-1.4±2.7 千克；P<0.01）。意向治疗分析（随访时丢失 1 次体重测量）表明，与安慰剂组相比，奥利司他组的脂肪量减少更多（-1.3±2.9 千克与-0.6±1.8 千克，分别；P<0.05），但瘦体重减少更少（-0.2±2.0 千克与-0.8±1.8 千克，分别；P<0.01）。奥利司他 60 毫克可能是一个以教育为基础的体重管理计划在一个主要是年轻男性士兵人群中的有效辅助治疗方法。
